PMC:7799377 / 38799-39618 JSONTXT

{"project":"LitCovid-sentences","denotations":[{"id":"T260","span":{"begin":0,"end":136},"obj":"Sentence"},{"id":"T261","span":{"begin":137,"end":224},"obj":"Sentence"},{"id":"T262","span":{"begin":225,"end":547},"obj":"Sentence"},{"id":"T263","span":{"begin":548,"end":652},"obj":"Sentence"},{"id":"T264","span":{"begin":653,"end":819},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Treating neurological symptoms can be challenging as drugs that suppress the immune system may be contraindicated for COVID-19 patients. There is evidence that the use of corticosteroids may prolong viral shedding [119,120]. Symptoms for neurological problems may be addressed, with first-line strategies such as controlling body temperature, offering anticonvulsants, and treating hypoxia.21 Second-line treatments for neuroinflammation involve IV immunoglobulin or plasma exchange, but IV immunoglobulin may increase the risk of thromboembolism. Furthermore, there is emerging concern of the possibility of microthrombosis in COVID-19 patients [121]. Third-line strategies for neuroinflammation in COVID patients may carry higher risks, and include such pharmacological agents as cyclophosphamide and rituximab [121]."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T189","span":{"begin":382,"end":389},"obj":"Phenotype"},{"id":"T190","span":{"begin":531,"end":546},"obj":"Phenotype"}],"attributes":[{"id":"A189","pred":"hp_id","subj":"T189","obj":"http://purl.obolibrary.org/obo/HP_0012418"},{"id":"A190","pred":"hp_id","subj":"T190","obj":"http://purl.obolibrary.org/obo/HP_0001907"}],"text":"Treating neurological symptoms can be challenging as drugs that suppress the immune system may be contraindicated for COVID-19 patients. There is evidence that the use of corticosteroids may prolong viral shedding [119,120]. Symptoms for neurological problems may be addressed, with first-line strategies such as controlling body temperature, offering anticonvulsants, and treating hypoxia.21 Second-line treatments for neuroinflammation involve IV immunoglobulin or plasma exchange, but IV immunoglobulin may increase the risk of thromboembolism. Furthermore, there is emerging concern of the possibility of microthrombosis in COVID-19 patients [121]. Third-line strategies for neuroinflammation in COVID patients may carry higher risks, and include such pharmacological agents as cyclophosphamide and rituximab [121]."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1370","span":{"begin":127,"end":135},"obj":"Species"},{"id":"1371","span":{"begin":637,"end":645},"obj":"Species"},{"id":"1372","span":{"begin":706,"end":714},"obj":"Species"},{"id":"1373","span":{"begin":782,"end":798},"obj":"Chemical"},{"id":"1374","span":{"begin":803,"end":812},"obj":"Chemical"},{"id":"1375","span":{"begin":9,"end":30},"obj":"Disease"},{"id":"1376","span":{"begin":118,"end":126},"obj":"Disease"},{"id":"1377","span":{"begin":382,"end":389},"obj":"Disease"},{"id":"1378","span":{"begin":420,"end":437},"obj":"Disease"},{"id":"1379","span":{"begin":531,"end":546},"obj":"Disease"},{"id":"1380","span":{"begin":609,"end":624},"obj":"Disease"},{"id":"1381","span":{"begin":628,"end":636},"obj":"Disease"},{"id":"1382","span":{"begin":679,"end":696},"obj":"Disease"},{"id":"1383","span":{"begin":700,"end":705},"obj":"Disease"}],"attributes":[{"id":"A1370","pred":"tao:has_database_id","subj":"1370","obj":"Tax:9606"},{"id":"A1371","pred":"tao:has_database_id","subj":"1371","obj":"Tax:9606"},{"id":"A1372","pred":"tao:has_database_id","subj":"1372","obj":"Tax:9606"},{"id":"A1373","pred":"tao:has_database_id","subj":"1373","obj":"MESH:D003520"},{"id":"A1374","pred":"tao:has_database_id","subj":"1374","obj":"MESH:D000069283"},{"id":"A1375","pred":"tao:has_database_id","subj":"1375","obj":"MESH:D009422"},{"id":"A1376","pred":"tao:has_database_id","subj":"1376","obj":"MESH:C000657245"},{"id":"A1377","pred":"tao:has_database_id","subj":"1377","obj":"MESH:D000860"},{"id":"A1378","pred":"tao:has_database_id","subj":"1378","obj":"MESH:D020078"},{"id":"A1379","pred":"tao:has_database_id","subj":"1379","obj":"MESH:D013923"},{"id":"A1381","pred":"tao:has_database_id","subj":"1381","obj":"MESH:C000657245"},{"id":"A1382","pred":"tao:has_database_id","subj":"1382","obj":"MESH:D020078"},{"id":"A1383","pred":"tao:has_database_id","subj":"1383","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Treating neurological symptoms can be challenging as drugs that suppress the immune system may be contraindicated for COVID-19 patients. There is evidence that the use of corticosteroids may prolong viral shedding [119,120]. Symptoms for neurological problems may be addressed, with first-line strategies such as controlling body temperature, offering anticonvulsants, and treating hypoxia.21 Second-line treatments for neuroinflammation involve IV immunoglobulin or plasma exchange, but IV immunoglobulin may increase the risk of thromboembolism. Furthermore, there is emerging concern of the possibility of microthrombosis in COVID-19 patients [121]. Third-line strategies for neuroinflammation in COVID patients may carry higher risks, and include such pharmacological agents as cyclophosphamide and rituximab [121]."}